GlobeNewswire by notified

Immunicum Receives Advanced Therapy Medicinal Product Classification from the EMA for Cancer Relapse Vaccine Candidate DCP-001

Share

Press Release

28 June 2021

Immunicum ReceivesAdvanced Therapy Medicinal Product Classification from the EMA for Cancer Relapse Vaccine Candidate DCP-001

Immunicum AB (publ) today announcedthat it has received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency (EMA) for the Company’s lead cancer relapse vaccine candidate, DCP-001.

DCP-001 is derived from Immunicum’s proprietary human DCOne cell line and is currently being evaluated as a cancer relapse vaccine for the prevention of tumor recurrence in two ongoing clinical studies addressing acute myeloid leukemia and ovarian cancer. DCP-001 is administered as an intradermal vaccine and has been shown to trigger systemic immune responses against different tumor-associated antigens, potentially contributing to the immune system’s control over residual disease.

The EMA and the Committee for Advanced Therapies (CAT) have concluded that DCP-001 meets the ATMP classification criteria and classifies as a somatic cell therapy medicinal product. The ATMP classification provides further guidance regarding the regulatory path forward for DCP-001.

ABOUT DCP-001

DCP-001 is an “off-the-shelf”, cell-based cancer relapse vaccine candidate based on Immunicum’s proprietary DCOne cell line and manufacturing process. DCP-001 has been developed using Immunicum’s expertise in allogeneic dendritic cell biology, resulting in a highly immunogenic vaccine carrying multiple endogenous tumor-associated antigens, which have the potential to boost the immune system to control residual disease and prevent or reduce tumor recurrence. It has demonstrated an excellent safety profile in clinical studies and is currently evaluated in an ongoing international Phase II clinical trial in acute myeloid leukemia (AML) patients, as well as a Phase I clinical trial in patients with High-Grade Serous Ovarian Cancer (HGSOC).

FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting
Chief Executive Officer
Telephone: +31 713 322 627
E-mail: info@immunicum.com

INVESTOR RELATIONS

Sijme Zeilemaker
Head of Investor Relations & Corporate Communication
Telephone: +46 8 732 8400
E-mail: ir@immunicum.com

MEDIA RELATIONS

Eva Mulder and Sophia Hergenhan
Trophic Communications
Telephone: +49 175 222 57 56
E-mail: immu@trophic.eu

ABOUT IMMUNICUM AB (PUBL)

Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Prime Office årsregnskab 202319.3.2024 10:00:00 CET | pressemeddelelse

Selskabsmeddelelse 199/2024 19. marts 2024 PRIME OFFICE A/S: TILFREDSSTILLENDE RESULTAT I EN OMSKIFTELIG VERDEN Økonomisk rapportering pr. 31.12.2023 Resultat af primær drift på 120,7 mio. DKK mod 114,0 i 2022.Resultat før skat på 114,3 mio. DKK mod 166,2 mio. i 2022. VÆKST I BOLIGSEGMENTET – K/S Danske Immobilien Huslejer stiger med 8,5% efter alle koncernens boligejendomme samles i K/S Danske Immobilien, og 4% i stigning uden intern handel. Omsætning/huslejer andrager 111,3 mio. DKK i 2023 mod 102,6 mio. DKK i 2022Udlejningsprocent på 98,5%Investeringer og vedligeholdelse over budget VÆKST I KONTORSEGMENTET - PO KONTORSELSKABER Huslejer stiger med 6,4% Omsætning/huslejer andrager 48,0 mio. DKK i 2023 mod 45,1 mio. DKK i 2022Udlejningsprocent på 99,5% FALD I ERHVERVSSEGMENTET – MC PROPERTY FUND HAMBURG Huslejer falder med 7% efter internt frasalg af boliger til K/S Danske Immobilien Omsætning efter frasalg af ejendomme 38,0 i 2023 40,9 mio. DKK i 2022.Udlejningsprocent på 97,6%. STIGE

Leading in health technology innovation: Philips one of the top patent applicants at European Patent Office19.3.2024 10:00:00 CET | Press release

March 19, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it is one of the leading patent applicants at the European Patent Office (EPO). Building on more than 130 years of innovation, Philips’ extensive global R&D programs and collaborations position the company at the forefront of health technology innovation. In 2023, Philips improved the health and well-being of 1.9 billion people with its innovations. With 607 MedTech patent applications in 2023, Philips is the second largest applicant in EPO's Patent Index 2023 in the field of medical technology. In total, Philips contributed 1,299 patent applications across various domains, solidifying its standing among the top 10 patent filers overall. Roy Jakobs, CEO of Royal Philips, said "At Philips, our purpose is to improve people’s health and well-being through meaningful innovation. As such, we see huge opportunities to make a difference through innovatio

Annual report 202319.3.2024 09:56:49 CET | Press release

To Nasdaq OMX Copenhagen A/S Public announcement no. 553 March 19th, 2024 ANNUAL REPORT FOR GLUNZ & JENSEN HOLDING A/S FOR THE FISCAL YEAR 2023 The annual report for the fiscal year 2023 was reviewed and approved at the Board of Directors meeting today. The Board of Directors announces the following consolidated financial statements for 2023 set for approval at the Annual General Meeting on April 10th, 2024. Please observe that the 2023 figures cover a 12-month period, whereas the 2022 figures cover a 9-month period. The annual report 2023 has the following key figures: The Group realized a revenue of DKK 143,3 million (2022: DKK 103,4 million). Gross profit totalled DKK 31,9 million (2022: DKK 27,5 million), equal to a gross profit margin of 22,2% (2022: 26,6%). EBITDA was DKK 10,8 million (2022: DKK 18,2 million). Profit before tax for the year totalled DKK 3,5 million (2022: DKK 15,3 million). The result is in line with the guidance to the market. The financial statements for 2023 a

CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES19.3.2024 09:30:00 CET | Press release

Bid date, 2024-03-19Auction date2024-03-19Settlement date2024-03-20Maturity Date2024-03-27Nominal amount956 billion SEKInterest rate4.00 %Bid times09.30-10.00 (CET/CEST) on the Bid dateBids are made to phone number08-696 69 70Confirmation of bids to e-mailrbcert@riksbank.seThe lowest accepted bid volume1 million SEKThe highest accepted bid volume956 billion SEKAllocation Time10.15 (CET/CEST) on the Bid dateProjected minimum liquidity surplus during the term956 billion SEKExpected excess liquidity at full allotment0 billion SEK Stockholm, 2024-03-19

HiddenA line styled icon from Orion Icon Library.Eye